Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention. (FOCUS)
Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug
Sponsor: ARTTIC International Management Services
A PHASE3 clinical study on Myocardial Infarction, this trial is completed. The trial is conducted by ARTTIC International Management Services and has accumulated 6 data snapshots since 2012. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ARTTIC International Management Services
- Federación Argentina de Cardiología FAC
- Ferrer Internacional S.A.
- Fundacion Clinic per a la Recerca Biomédica
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
- Instituto de Salud Carlos III
- Mario Negri Institute for Pharmacological Research
- Rusculleda Foundation Instituto DAMIC
- World Health Organization
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alcalá de Henares, Spain , Aldaia, Spain , Alicante, Spain , Asunción, Paraguay , Barcelona, Spain , Buenos Aires, Argentina , Casarano, Italy , Cheste, Spain , Cremona, Italy , Córdoba, Argentina and 29 more locations